仑卡奈单抗获批对阿尔茨海默病患者诊疗的意义:渐进一步还是范式转变?
综述讨论淀粉样蛋白级联假说及其治疗推论,指出多奈单抗和仑卡奈单抗临床试验报告了与淀粉样蛋白清除相关的临床获益;仑卡奈单抗3期试验显示18个月内延缓认知和功能恶化约5个月,但个体获益程度和持久性需临床实践长期观察,且需关注ARIA和医疗资源压力。
要点
- 仑卡奈单抗每2周静脉给药,在18个月双盲安慰剂对照试验中延缓认知和功能恶化约5个月。
- 淀粉样蛋白相关影像学异常(ARIA)约20%发生,多无症状,略超半数归因于治疗,其余归因于AD相关淀粉样血管病。
- APOE ε4纯合子者ARIA风险更高,长期使用仑卡奈单抗的出血并发症需更好理解。
核心结论
- 仑卡奈单抗治疗延缓轻度AD症状患者的临床进展是重要概念性成就,但个体获益程度和持久性需临床实践长期观察。
研究设计与样本
- 综述,讨论淀粉样蛋白级联模型、抗淀粉样蛋白单克隆抗体临床试验结果及仑卡奈单抗3期试验。
主要发现
- 仑卡奈单抗是首个发表3期试验结果的抗淀粉样蛋白单克隆抗体,在18个月双盲安慰剂对照试验中使脑淀粉样蛋白升高且伴轻度认知障碍或轻度痴呆的患者认知和功能恶化延缓约5个月。
- ARIA约20%发生,多无症状,略超半数归因于治疗,其余归因于AD相关淀粉样血管病。
- APOE ε4纯合子者ARIA风险更高。
- 长期使用仑卡奈单抗的出血并发症需更好理解。
临床怎么用
- 仑卡奈单抗每2周静脉给药用于脑淀粉样蛋白升高且伴轻度认知障碍或轻度痴呆的患者。
- 仑卡奈单抗给药将对痴呆照护人员和基础设施带来空前压力,两者需指数级增长以应对挑战。
局限性
- 个体获益程度和持久性需临床实践长期观察。
- 长期使用仑卡奈单抗的出血并发症需更好理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The amyloid cascade model of the pathogenesis of Alzheimer disease (AD) is well supported in observational studies. Its therapeutic corollary asserts that removal of amyloid-β peptide ("amyloid") would provide clinical benefits. After 2 decades of pursuing the strategy of amyloid removal without success, clinical trials of the antiamyloid monoclonal antibody (AAMA) donanemab and a phase 3 clinical trial of lecanemab have reported clinical benefits linked to amyloid removal. Lecanemab (trade name, Leqembi) is the first with published phase 3 trial results. When administered through IV every 2 weeks to patients with elevated brain amyloid and mild cognitive impairment or mild dementia, lecanemab delayed cognitive and functional worsening by approximately 5 months in an 18-month double-blind, placebo-controlled trial. The trial was well conducted, and the results favoring lecanemab were internally consistent. The demonstration that lecanemab treatment delayed clinical progression in persons with mild symptoms due to AD is a major conceptual achievement, but a better appreciation of the magnitude and durability of benefits for individual patients will require extended observations from clinical practice settings. Amyloid-related imaging abnormalities (ARIA) that were largely asymptomatic occurred in approximately 20%, slightly more than half of which were attributable to treatment and the rest to underlying AD-related amyloid angiopathy. Persons who were homozygous for the APOE ε4 allele had greater ARIA risks. Hemorrhagic complications with longer-term lecanemab use need to be better understood. Administration of lecanemab will place unprecedented pressures on dementia care personnel and infrastructure, both of which need to grow exponentially to meet the challenge.
引用
- Knopman DS, Hershey L. Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift? Neurology. 2023. PMID: 37295957. doi:10.1212/WNL.0000000000207438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。